Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy.
about
NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell EngraftmentPerspectives on Regulatory T Cell Therapies.Subconjunctivally applied naïve Tregs support corneal graft survival in baby ratsStability of human rapamycin-expanded CD4+CD25+ T regulatory cellsPhase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.Regulatory T Cell Immunotherapy in Immune-Mediated DiseasesTreatment of graft-versus-host disease with naturally occurring T regulatory cells.Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells.Immunoglobulin G promotes skin graft acceptance in an immunologically potent rat model.Influence of hemodialysis on circulating CD4(low)CD25 (high) regulatory T cells in end-stage renal disease patients.Utilization of leukapheresis and CD4 positive selection in Treg isolation and the ex-vivo expansion for a clinical application in transplantation and autoimmune disorders.T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells?Role of regulatory T cells in the promotion of transplant tolerance.Clinical application of regulatory T cells in type 1 diabetes.Hurdles in therapy with regulatory T cells.Cell-Based Therapies with T Regulatory Cells.Obtaining regulatory T cells from uraemic patients awaiting kidney transplantation for use in clinical trials.Ex Vivo Costimulatory Blockade to Generate Regulatory T Cells From Patients Awaiting Kidney Transplantation.Adoptive T Regulatory Cell Therapy for Tolerance Induction.Regulatory T Cell Therapy for Ischemic Stroke: how far from Clinical Translation?Mild hypothermia provides Treg stability.Allogeneic bone marrow grafts with high levels of CD4(+) CD25(+) FoxP3(+) T cells can lead to engraftment failure.Peripheral Treg count and it's determinants in unsensitized and sensitized chronic kidney disease patients.Generation of Human Alloantigen-Specific Regulatory T Cells Under Good Manufacturing Practice-Compliant Conditions for Cell Therapy.Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders.The time is crucial for ex vivo expansion of T regulatory cells for therapy.Immunotherapy with iTreg and nTreg Cells in a Murine Model of Inflammatory Bowel Disease.Cell banking for regulatory T cell-based therapy: strategies to overcome the impact of cryopreservation on the Treg viability and phenotype.Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis.Comparative study of regulatory T cells expanded ex vivo from cord blood and adult peripheral bloodFoxp3-transduced polyclonal regulatory T cells suppress NK cell functions in a TGF-beta dependent manner
P2860
Q26765845-FB598876-76FA-42FE-BA27-AAA7BFF06E29Q34263542-A1D2C24A-9F13-4A8F-AC41-1E10667659BAQ34787928-73792D2F-7C61-4285-BECA-EDE3DAF157A1Q35193745-2F825D4B-EC75-485F-B6AF-640CA5008F21Q35224606-C3FEAFDF-8076-4C22-A19B-2FFE2F0CE6DCQ36462109-B6CE959E-8589-4F23-80B6-03EAD35ECE04Q37321716-227AD6F2-C556-4BC8-AC03-642CDA167348Q37349656-B46FBA7B-1C1B-435E-80AB-A9456662064CQ37457538-C264467A-5B7D-45A4-B145-7F87BB27DB80Q37488778-1995FADD-86BD-4828-8A1A-DFA9EFB602C8Q37694801-F142246C-FBA7-4177-9FF1-2B787BE6AA38Q37710764-2F2CB58F-A1E9-4B60-A359-1A12D20974EAQ38004403-35728BA4-02CB-4B10-8290-E83DE30C872DQ38102783-9C55F747-D8A2-4568-AC4D-9C16FDCFA7F4Q38583881-949A8A9D-A3BA-4324-8317-ECA5FF5737F5Q38766028-05F0867F-A6C0-4893-BE89-2F48854E266CQ39431833-6D1E6F76-06DA-4884-956A-85E6362C13EFQ40083199-A1705EED-AC81-4B81-97C6-3AACB8A934B6Q40132561-D7D95BA4-90EC-435B-8FA8-1FF56CE21B34Q41658163-AB918885-192C-46AD-AB3F-3592B5FFA473Q41696924-91D9429B-196C-4AB1-9730-0DF2BC9FFE02Q44852729-4366FC0E-FB38-4045-8788-E3FBA27E17AEQ45147425-C0481991-E7F7-4737-8A56-8E7F1FDE87FEQ46059376-4EEB4315-8C3E-4BD5-8DAC-5175664FCE7FQ47138817-69A62BF0-8D45-45E0-8D93-54D64E23D44FQ51014475-DB553DA0-5722-4927-8D15-E16DE87FE5F2Q51727790-4B0AD10C-7062-4418-A007-3C6BE92DFF93Q52668207-EBEC536A-7ECD-4BA9-81BB-16F95A38892BQ55049471-A8696ED4-3020-42C6-93F1-D551F5B266D1Q56898066-D3F11312-004A-4B79-9E60-194FB1F3ABE6Q56899556-0FD59130-19C4-4233-91C1-0DCC1A85AE09
P2860
Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ex vivo expansion of CD4
@nl
Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy.
@en
type
label
Ex vivo expansion of CD4
@nl
Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy.
@en
prefLabel
Ex vivo expansion of CD4
@nl
Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy.
@en
P2093
P2860
P356
P1433
P1476
Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy.
@en
P2093
Andrzej Myśliwski
Jolanta Myśliwska
Magdalena Szaryńska
P2860
P304
P356
10.1002/CYTO.A.20659
P577
2009-03-01T00:00:00Z